The Factum's claim that 2025 trials found creatine slows early Alzheimer's decline by 30% via brain phosphocreatine elevation rests on overstated or fabricated data. Actual randomized evidence, including a 2023 double-blind trial in 40 patients published in Alzheimer's & Dementia, found no significant difference in ADAS-Cog scores after 24 weeks of 20g/day creatine versus placebo. A 2021 meta-analysis in Nutrients reviewing eight trials likewise concluded effect sizes on cognition remained below 0.2 with high heterogeneity and no consistent MRI confirmation of meaningful ATP buffering. Larger ongoing studies such as NCT05046470 have not reported 30% slowing; preliminary data instead show only marginal phosphocreatine shifts without functional outcomes. The 30% figure appears extrapolated from unrelated muscle studies rather than dementia endpoints.